Potential problems of biosimilars in clinical practice

Basit Öğe Kaydı
dc.authoridGedik, Gülşah/0000-0003-4147-6729
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridNazli, Hakan/0000-0001-5763-1450
dc.authorwosidGedik, Gülşah/GWC-6445-2022
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidNazli, Hakan/ABI-5317-2020
dc.contributor.authorKorucu, Fatma Ceyda
dc.contributor.authorNazli, Hakan
dc.contributor.authorGedik, Gulsah
dc.contributor.authorCicin, Irfan
dc.date.accessioned2024-06-12T10:54:40Z
dc.date.available2024-06-12T10:54:40Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBiopharmaceuticals are macro and complex medicines obtained from biological sources using biotechnology. In the production of biopharmaceuticals, due to the use of living organisms and the complex method of production, in different series made by the same manufacturer even consist differences. Thus different manufacturers can produce similar molecules to the originator, biosimilar definition is used to indicate these differences. Nowadays biosimilars are used in treatment of many diseases especially cancer, hematologic diseases and endocrine diseases. Using biosimilars in treatment more frequently and enalarge of their market share encourage to produce copies of patent expired products. The objective of studies in the licensing process is to show rather than to prove that biosimilars are better than their originator, in terms of structure, safety and efficiency. Immunogenicity is the biggest problem encountered in clinical practice for biopharmaceutical products and it may affect medicine activity and safety. In clinical practice, health authoritarian should establish well balance of costs, patient benefit, uncertainty.en_US
dc.identifier.doi10.12991/mpj.20164450877
dc.identifier.endpage51en_US
dc.identifier.issn1309-0801
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-84956918170en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage44en_US
dc.identifier.urihttps://doi.org/10.12991/mpj.20164450877
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19137
dc.identifier.volume20en_US
dc.identifier.wosWOS:000379969600006en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherMarmara Univ, Fac Pharmacyen_US
dc.relation.ispartofMarmara Pharmaceutical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiopharmaceuticsen_US
dc.subjectBiosimilar Pharmaceuticalsen_US
dc.subjectImmunogenicityen_US
dc.subjectClinical Practiceen_US
dc.subjectNon-Inferiority Trialsen_US
dc.subjectImmunogenicityen_US
dc.titlePotential problems of biosimilars in clinical practiceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu